In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CRO Medpace nets $173.6mm in IPO

Executive Summary

Contract research organization Medpace Inc. netted $173.6mm through the sale of 8mm shares (includes full exercise of the 1.05mm-share over-allotment option) at $23 (the top of the range) in its initial public offering.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register